Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

Ziyu Wen, Xuan Zhou, Bingyu Lin, Qiang WANG, Liping Ma, Huilan Zeng, Zhi Liu, Bolin He, Qing Zhang, Mei Zhong, Xiaoli Liu, Na Xu

Blood (2025) 146 (Supplement 1): 7358.

https://doi.org/10.1182/blood-2025-7358

Published: 2025

Journal Articles

All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma

Ling Zhong, Qiang Wang, Miao Xian, Xiaobing Huang, Jianfei Qian, Jiao Chen, Qing Yi

Blood (2025) 146 (Supplement 1): 5817.

https://doi.org/10.1182/blood-2025-5817

Published: 2025

Journal Articles

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Shuhua Yi, Liping Su, Bingzong Li, Zhiming Li, Zhengming Jin, Ming Jiang, Wenjuan Yu, Zengjun Li, Jun Luo, Wei Yang, Fei Li, Cailing Wang, Hui Wu, Qiang Wang, Bing Yu, Jianghua Chen, June Xu, Lugui Qiu

Blood (2025) 146 (Supplement 1): 1808.

https://doi.org/10.1182/blood-2025-1808

Published: 2025

Journal Articles

Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study

Ziyu Wen, Bingyu Lin, Qiang WANG, Xuan Zhou, Xiaoli Liu, Xin Du, Na Xu

Blood (2025) 146 (Supplement 1): 3776.

https://doi.org/10.1182/blood-2025-3776

Published: 2025

Journal Articles

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Qian Jiang, Weiming Li, Yanli Zhang, Qiang WANG, Suning Chen, Bingcheng LIU, Jie Jin, Zhenfang Liu, Zhuogang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Shujie Yan, xiaomeng Dong, Yihan Wang, Jingrong Cao

Blood (2025) 146 (Supplement 1): 902.

https://doi.org/10.1182/blood-2025-902

Published: 2025

Journal Articles

MSC affect the sensitivity of CML cells to TKIs through mitochondrial transfered via tunneling nanotubes

Zhechen Miao, Qiang WANG, Qifa Liu

Blood (2025) 146 (Supplement 1): 6758.

https://doi.org/10.1182/blood-2025-6758

Published: 2025

Journal Articles

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Zicheng Gao, Xuan Zhou, Qiang Wang, Dan Xu, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2024) 144 (Supplement 1): 6643.

https://doi.org/10.1182/blood-2024-207289

Published: 2024

Journal Articles

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 6639.

https://doi.org/10.1182/blood-2024-205673

Published: 2024

Journal Articles

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

Zherou He, Qing Zhang, Xuan Zhou, Qiang Wang, Xiaoli Liu, Na Xu

Blood (2024) 144 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2024-207302

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Ziyu Wen, Xuan Zhou, Bingyu Lin, Xiaoli Liu, Qiang Wang, Na Xu

Blood (2024) 144 (Supplement 1): 1803.

https://doi.org/10.1182/blood-2024-205725

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao

Blood (2024) 144 (Supplement 1): 477.

https://doi.org/10.1182/blood-2024-205300

Published: 2024

Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao

Blood (2023) 142 (Supplement 1): 867.

https://doi.org/10.1182/blood-2023-185977

Published: 2023

Journal Articles

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ziyu Wen, Zhiping Fan, Qiang Wang, Xuan Zhou, Zherou He, Zicheng Gao, Hong Chen, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Hongsheng Zhou, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2023-181850

Published: 2023

Journal Articles

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Zicheng Gao, Zherou He, Xuan Zhou, Ziyu Wen, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 6411.

https://doi.org/10.1182/blood-2023-184700

Published: 2023

Journal Articles

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Bailin He, Hongsheng Zhou, Ren Lin, Zhixiang Wang, Na Xu, Qiang Wang, Jing Sun, Xiaoli Liu, Peng Li, Qifa Liu

Blood (2023) 142 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2023-184492

Published: 2023

Journal Articles

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

Xuan Zhou, Na Xu, Ziyu Wen, Hanyin Liang, Dongmei Luo, Hong Chen, Zherou He, Zicheng Gao, Qiang Wang, Dan Xu, Xiaoli Liu, Qifa Liu

Blood (2023) 142 (Supplement 1): 6379.

https://doi.org/10.1182/blood-2023-184643

Published: 2023

Journal Articles

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Zherou He, Xuan Zhou, Ziyu Wen, Zicheng Gao, Hong Chen, Qiang Wang, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Na Xu, Qifa Liu

Blood (2023) 142 (Supplement 1): 1807.

https://doi.org/10.1182/blood-2023-182765

Published: 2023

Journal Articles

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Jie Luo, Ziyu Wen, Mengxia Zhao, Zicheng Gao, Hong Chen, Qiang Wang, Xuan Zhou, Zherou He, Hanyin Liang, Dongmei Luo, Xiaoli Liu, Qifa Liu, Na Xu

Blood (2023) 142 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2023-182007

Published: 2023

Journal Articles

Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 10841–10842.

https://doi.org/10.1182/blood-2022-157246

Published: 2022

Journal Articles

Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood

Luo Dongmei, Na Xu, Xiaoli Liu, Jie Luo, Hanyin Liang, Zherou He, Hong Chen, Qiang Wang, Xuan Zhou

Blood (2022) 140 (Supplement 1): 6755–6756.

https://doi.org/10.1182/blood-2022-165137

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of peginterferon alfa-2b for chronic myeloid leukemia and essential thrombocythemia during pregnancy

All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma

A phase I study of HDM2005, a ROR1 targeted antibody-drug conjugate (ADC), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or classical Hodgkin lymphoma(cHL)

Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic Phase: A propensity score-matched cohort study

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

MSC affect the sensitivity of CML cells to TKIs through mitochondrial transfered via tunneling nanotubes

Clinical Characteristics and Risk Factors of Chronic Kidney Disease Among Patients with Myeloproliferative Neoplasms

Safety and Efficacy of Luspatercept for the Treatment of Refractory Anemia in Patients with Myelofibrosis

Analysis of the Impact of TKI Dose Adjustment Under the Guidance of Blood Concentration Monitoring on the Efficacy, Safety and Quality of Life in Patients with CML

The Efficacy and Safety of Selinexor Plus Ruxolitinib Regimen in Ruxolitinib-Resistant Myelofibrosis: A Retrospective Study

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study

Ruxolitinib or Interferon-α Treatment As a Protective Strategy for Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN) during the COVID-19 Pandemic

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Flumatinib for the Treatment of Adult Patients with Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia: Results from Real-World Data

TKI Dose Optimization Based on Therapeutic Drug Monitoring（TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients

Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology

Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only